Targeted therapy with IDH1/2 (isocitrate dehydrogenase1/2) or FLT3 (fms-related tyrosine kinase3) presents a promising treatment option for elderly AML patients who have specific mutation targets [13]. The gene discussed is FLT3; the disease is acute myeloid leukemia.